Loading…
STALEVO is a brand name for Levodopa, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
Dosing Considerations · As with levodopa/carbidopa, non-selective monoamine oxidase (MAO) inhibitors are contraindicated for use with STALEVO (levodopa, carbidopa and entacapone). These inhibitors must be discontinued at least two weeks prior to initiating therapy with STALEVO.
, selegiline HCl). · For special patient populations see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS - Gastrointestinal, Neurologic and Renal. · STALEVO tablets should not be divided. The tablets should always be swallowed whole. · STALEVO may be taken with or without food.
, biscuits) or liquid may help control gastrointestinal side effects. Recommended Dose and Dosage Adjustment The daily dosage must be titrated for each patient to achieve optimal therapeutic response to levodopa. 5/200 mg levodopa/carbidopa/entacapone).
Patients should be instructed to take only one STALEVO tablet at each dosing time. Patients receiving less than 70-100 mg carbidopa a day are more likely to experience nausea and vomiting. The experience with total daily dosage greater than 200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 1600 mg and therefore the maximum STALEVO dose is 8 tablets per day.
STALEVO is intended mainly for use in patients already receiving treatment with corresponding doses of standard-release levodopa/DDC inhibitor and entacapone. Starting STALEVO therapy Switching from levodopa/ DDC inhibitor (carbidopa or benserazide) preparations and entacapone to STALEVO a.
Patients who are currently receiving treatment with entacapone and standard-release levodopa/carbidopa in doses equal to STALEVO tablet strengths can be directly switched to the corresponding STALEVO tablets. For example, patients taking one tablet of 100/25 mg levodopa/carbidopa with one tablet of entacapone 200 mg four times daily can be switched to one 100/25/200 mg STALEVO tablet four times daily.
27 b. 5/200 mg), STALEVO dosing should be carefully titrated for optimal clinical response. At the start of therapy, STALEVO should be adjusted to correspond as closely as possible to the total daily dose of levodopa currently used. c.
When initiating STALEVO in patients currently treated with entacapone and levodopa/benserazide in a standard-release formulation, treatment should be stopped for one night and STALEVO therapy started the next morning. The therapy should begin with a dosage of STALEVO that will provide either the same amount of levodopa or slightly (5- 10%) more.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Levodopa in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Switching in patients not currently treated with entacapone to STALEVO Initiation of STALEVO at a dosage corresponding to current treatment may be considered in some patients with Parkinson's disease and end-of-dose “wearing-off” who are not stabilised on their current standard-release levodopa/DDC inhibitor treatment.
However, a direct switch from levodopa/DDC inhibitor to STALEVO is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 600 mg. In such patients it is advisable to introduce entacapone treatment as a separate medication (entacapone tablets) and adjust the levodopa dose if necessary, before switching to STALEVO.
, dyskinesias, “on-off” phenomenon, nausea, vomiting, and hallucinations to occur at lower doses and earlier than with preparations containing levodopa alone. It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dosage by 10-30% within the first days to first weeks after initiating STALEVO treatment.
The daily dose of levodopa can be reduced by extending the dosing intervals and/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient. Dosage adjustment during the course of the treatment When more levodopa is required, an increase in the frequency of doses and/or the use of an alternative strength of STALEVO should be considered, within the dosage recommendations.
When less levodopa is required, the total daily dosage of STALEVO should be reduced either by decreasing the frequency of administration by extending the time between doses, or by decreasing the strength of STALEVO at an administration.
If other levodopa products are used concomitantly with a STALEVO tablet, the maximum dosage recommendations should be followed. Discontinuation of STALEVO therapy If STALEVO treatment (levodopa/carbidopa/entacapone) is discontinued and the patient is switched to levodopa/DDC inhibitor therapy without entacapone, it is necessary to adjust the 28 dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms (see WARNINGS AND PRECAUTIONS).
Missed Dose If there is more than an hour left until the next dose, the missed dose should be taken immediately and the next tablet at the next scheduled dose. If there is less than an hour until the next dose, the missed dose should be taken immediately and an hour must elapse until the next dose is taken, following which the patient can go back to the normal schedule.
Doses should not be doubled. Always leave at least an hour between STALEVO tablets, to avoid possible side effects. Administration Each tablet is to be taken orally either with or without food (see ACTIONS AND CLINICAL PHARMACOLOGY, […]